Literature DB >> 9122841

Proliferating cell nuclear antigen (PCNA) in cerebral cavernomas: an immunocytochemical study of 42 cases.

L Notelet1, J P Houtteville, S Khoury, B Lechevalier, F Chapon.   

Abstract

BACKGROUND: The natural history and growth mechanisms of cerebral cavernous angiomas are unclear, which makes them difficult to manage. We attempted to evaluate the evolutive potential of cavernomas by studying the proliferative capacity of cells.
METHODS: We studied 42 histologically verified cavernomas with monoclonal antibody to proliferating cell nuclear antigen (PCNA), an accessory protein of the cell cycle, the rate of which is increased in proliferative cells. The PCNA Labeling Index (PCNA LI) was calculated in each case, and the results were compared with histologic findings (lacy areas, thick walls, thrombi, hemosiderin) and clinical features (epilepsy, hematomas, pseudotumorous signs).
RESULTS: Thirty-six of 42 cases (85.7%) revealed stained cells. PCNA LI ranged from 1 to 48% (mean: 23.39%). Statistical analyses showed a positive correlation between PCNA LI and the extent of lacy areas (p < 0.05). On the contrary, collagenous-walled and thrombotic areas rarely showed positively stained cells. We found no relationship between PCNA LI and clinical features.
CONCLUSIONS: A proliferative capacity of endothelial cells does exist in some areas of cavernomas and may explain, besides thromboses and hemhorrages, the growth and even de novo appearance of these lesions. Occurrence of fragile blood cavities, thickening of others, and changes in blood flow may influence the evolution of lesions. Our results suggest that in cavernomas, some areas may undergo specific changes, which makes them more dynamic lesions than previously thought.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9122841     DOI: 10.1016/s0090-3019(96)00248-0

Source DB:  PubMed          Journal:  Surg Neurol        ISSN: 0090-3019


  8 in total

1.  Surgical management of symptomatic brain stem cavernoma in a developing country: technical difficulties and outcome.

Authors:  Ahmed Farhoud; Hisham Aboul-Enein
Journal:  Neurosurg Rev       Date:  2016-04-06       Impact factor: 3.042

Review 2.  Spontaneous bleeding into a suprasellar cavernous angioma of a neonate: case report and literature review.

Authors:  Suhas Udayakumaran; Dimitrios Paraskevopoulos; Emanuela Cagnano; Jonathan Roth; Shlomi Constantini
Journal:  Childs Nerv Syst       Date:  2010-04-24       Impact factor: 1.475

3.  Extra-axial cavernous hemangioma: two case reports.

Authors:  I Kanaan; A Jallu; J Alwatban; Z Patay; R Hessler
Journal:  Skull Base       Date:  2001-11

4.  Biological activity of paediatric cerebral cavernomas: an immunohistochemical study of 28 patients.

Authors:  Wuttipong Tirakotai; Sandra Fremann; Niels Soerensen; Wolfgang Roggendorf; Adrian M Siegel; Hans Dieter Mennel; Yuan Zhu; Helmut Bertalanffy; Ulrich Sure
Journal:  Childs Nerv Syst       Date:  2006-02-18       Impact factor: 1.475

5.  Capillary malformation-arteriovenous malformation, a new clinical and genetic disorder caused by RASA1 mutations.

Authors:  Iiro Eerola; Laurence M Boon; John B Mulliken; Patricia E Burrows; Anne Dompmartin; Shoji Watanabe; Romain Vanwijck; Miikka Vikkula
Journal:  Am J Hum Genet       Date:  2003-11-24       Impact factor: 11.025

6.  Optic chiasmal cavernous angioma: A rare suprasellar vascular malformation.

Authors:  Hussam Abou-Al-Shaar; Ayman Bahatheq; Radwan Takroni; Ibrahim Al-Thubaiti
Journal:  Surg Neurol Int       Date:  2016-08-01

7.  A two-hit mechanism causes cerebral cavernous malformations: complete inactivation of CCM1, CCM2 or CCM3 in affected endothelial cells.

Authors:  Axel Pagenstecher; Sonja Stahl; Ulrich Sure; Ute Felbor
Journal:  Hum Mol Genet       Date:  2008-12-16       Impact factor: 6.150

8.  Systemic Expression of Vascular Endothelial Growth Factor in Patients with Cerebral Cavernous Malformation Treated by Stereotactic Radiosurgery.

Authors:  Sang-Jin Park; Seong-Hyun Park
Journal:  J Korean Neurosurg Soc       Date:  2016-09-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.